ReviewTranslational cancer research2022

Efficacy and safety of regorafenib and fruquintinib as third-line treatment for colorectal cancer: a narrative review.

Xiaojing Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.